1. Foreword

   • Christopher-Paul Milne

   EditorialNotes 23 September 2012 Pages: v - vii

2. The economics of follow-on drug research and development

   • Joseph A. DiMasi
   • Cherie Paquette

   Original Research Article 23 September 2012 Pages: 1 - 14

   

3. Are the economics of pharmaceutical research and development changing?

   • Henry Grabowski

   Review Article 23 September 2012 Pages: 15 - 24

   

4. The effects of pharmaceutical consumption and obesity on the quality of life in the Organization of Economic Cooperation and Development (OECD) countries

   • H. E. Frech III
   • Richard D. Miller Jr

   Original Research Article 23 September 2012 Pages: 25 - 36

   

5. Changes in the costs of treating mental health disorders

   • Ernst R. Berndt

   Review Article 23 September 2012 Pages: 37 - 50

   

6. Impediments to the diffusion of innovative medicines in Europe

   • Oliver Schöffski

   Review Article 23 September 2012 Pages: 51 - 64

   

7. The impact of healthcare reform in The Netherlands

   • Frans Rutten

   Review Article 23 September 2012 Pages: 65 - 71

   

8. Global principles for better healthcare

   • Edward Bramley-Harker

   Review Article 23 September 2012 Pages: 73 - 79

   

9. The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation

   • Jerry Avorn

   Review Article 23 September 2012 Pages: 81 - 86

10. The policy implications of gender mainstreaming for healthcare research in the EU

    • Ineke Klinge
    • Peggy Maguire

    Review Article 23 September 2012 Pages: 87 - 93

    

11. Concluding remarks

    • Kenneth I. Kaitin

    Concluding Remarks 23 September 2012 Pages: 95 - 96